Interestingly, multiple other t-CDKs have been implicated in tumour angiogenesis: inhibition of CDK7/CDK9 suppresses vascular endothelial growth factor (VEGF)-induced angiogenic effects on endothelial cells [[154], [155]], while CDK12-mediated activation of VEGF and PI3K/AKT/mTOR signalling has been implicated in angiogenesis in prostate and gastric cancer, respectively [156,157]. Here, CDK9 is linked to neoplasm.